Myelofibrosis: 15 Years of Allogeneic Transplantation - Single Center Experience

• Published in: Blood 2016-12, Vol.128 (22), p.5870-5870
• Main Authors: Tenreiro, Rita, Ferreira, Rosa, Leite, Luís, Vaz, Carlos, Campilho, Fernando, Roncón, Susana, Campos, Antonio M.
• Format: Article
• Language: English
• ISSN: 0006-4971; 1528-0020
• DOI: 10.1182/blood.V128.22.5870.5870

Background: Myelofibrosis (MF) is a clonal hematopoietic stem cell disorder associated with a significative risk of evolution to acute leukemia. It can either present as primary disease or secondary to other myeloproliferative neoplasms. It's predominantly a disease of the elderly, with a median age at diagnosis of 65 years. Pharmacological therapy directed at symptom control has not shown to improve survival and, despite therapeutic advances with the Janus-Kinase (JAK) inhibitors, allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the only potentially curative treatment. Due to most patients advanced age and comorbidities, increased risk of graft failure, HSCT is challenging and requires specialized teams. Aim: To assess the results of allo-HSCT in myelofibrosis patients in our center and identify prognostic factors. Methods: Observational retrospective study including patients with previous diagnosis of MF (primary or secondary), referred to our center who underwent allo-HSCT between May 2001 and May 2016. Pre-transplant DIPSS, HCT-CI and Lille scores were applied. Neutrophil and platelet engraftment were defined as the first of three and seven consecutive days above 500/μL and 20,000/μL respectively. Correlations between factors were calculated using Spearman’s rho (ρ). Survival was estimated using Kaplan-Meyer method. Statistical significance was defined as p